ArticleHuman vaccines & immunotherapeutics2019
Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Health economic evaluation of health promotion and disease prevention in Germany: a scoping review.Health economics review · 2026Review
- Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal.PharmacoEconomics - open · 2026Article
- The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide.Infectious diseases and therapy · 2025Article
- How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?Human vaccines & immunotherapeutics · 2023Article
- Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.Human vaccines & immunotherapeutics · 2023Review
- Patient-reported outcomes in vaccines research: relevance for decision-making.Human vaccines & immunotherapeutics · 2022Review
- Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults.Dermatology and therapy · 2022Article
- Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.PharmacoEconomics · 2022Article
- Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review.Therapeutic advances in vaccines and immunotherapy · 2022Review
- Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.Human vaccines & immunotherapeutics · 2021Article
- Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.PloS one · 2021Article
- The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.Human vaccines & immunotherapeutics · 2020Article
- Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.Applied health economics and health policy · 2019Article
- Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older.Dermatology and therapy · 2019Article
- Varicella zoster virus vaccines: an update.ImmunoTargets and therapy · 2019Article
- Article
- Recombinant Zoster Vaccine (ShingrixDrugs & aging · 2018Review
- [Prevention of herpes zoster: New perspectives].Atencion primariaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in the German population ≥ 60 years of age (YOA) and to identify the optimal age of vaccination. We used a static, multi-cohort Markov model that followed a hypothetical cohort of 1 million people ≥ 60 YOA life-long after vaccination using German-specific inputs. Both costs and outcomes were discounted at 3%, the incremental cost-effectiveness ratio (ICER) was calculated based on the societal perspective. The coverage of RZV was set at 40% with a second-dose compliance of 70%. Vaccinating the population aged ≥ 60 YOA would result in 45,000 HZ cases avoided, 1,713 quality-adjusted life years (QALYs) gained at a total cost of approximately €63 million compared to 38,000 cases avoided, 1,545 QALYs gained at a total cost of approximately €68 million in the population ≥ 70 YOA. This would result in an ICER of approximately €37,000 and €44,000/QALY, for the age cohort ≥ 60 and ≥ 70 YOA, respectively. Scenario analyses demonstrated that vaccinating at age 60 or 65 YOA would show greater public health impact and would result in the lowest observed ICER compared to vaccinating at 70 YOA. In conclusion, starting vaccination with RZV in the German population ≥ 60 YOA would demonstrate the best value from a public health and economic standpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.